10 May 2022>: Original Paper
Long-Term Effectiveness, Safety, and Patient-Reported Outcomes of Self-Administered Subcutaneous Hepatitis B Immunoglobulin in Liver Post-Transplant Hepatitis B Prophylaxis: A Prospective Non-Interventional Study
Bruno Roche 1BCDE , Artur Bauhofer 2ACDEF* , Miguel Ãngel Gomez Bravo 3BCDE , Georges Philippe Pageaux 4ABCDE , Fabien Zoulim 5BDE , Alejandra Otero 6BC , Martin Prieto 78BC , Carmen Baliellas 9BC , Didier Samuel 1ACDEDOI: 10.12659/AOT.936162
Ann Transplant 2022; 27:e936162
Table 1 Demographic characteristics and relevant medical history data.
Full analysis set (N=195) | |
---|---|
59.0 (19, 81) | |
,* | 74.0 (43, 129) |
Male | 160 (82.1) |
Female | 35 (17.9) |
16.6 (±9.0) | |
14 (7.2) | |
HBV-induced liver cirrhosis | 100 (51.3) |
HCC | 83 (42.6) |
HBV-induced fulminant hepatitis | 12 (6.2) |
Whole liver | 179 (91.8) |
Split liver, deceased donor liver transplant | 8 (4.1) |
Living donor liver transplant | 5 (2.6) |
Liver and kidney co-transplant | 3 (1.5) |
91 (46.7) | |
106 (54.5) | |
Alcoholic liver disease | 39 (20.0) |
Non-alcoholic steatohepatitis | 7 (3.6) |
Autoimmune hepatitis | 2 (1.0) |
Primary sclerosing cholangitis | 2 (1.0) |
Other | 6 (3.1) |
Arterial hypertension | 38 (19.5) |
Diabetes mellitus | 34 (17.4) |
Kidney disease | 26 (13.3) |
Allergy | 10 (5.1) |
Cancer** | 3 (1.5) |
Hepatitis D virus | 43 (22.1) |
Hepatitis C virus | 19 (9.7) |
Human immunodeficiency virus | 7 (3.6) |
* Based on data of 188 patients; ** papillary thyroid carcinoma, prostatic adenocarcinoma, kidney carcinoma. HBV – hepatitis B virus; HCC – hepatocellular carcinoma; LT – liver transplantation; SD – standard deviation. |